Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment
Advanced Science · 2026-07-29
DOI: 10.1002/advs.76840 ↗At a glance
Journal article in Advanced Science, published online on 2026-07-29. Written by Jing Wu and 18 co-authors. Institution: Aix Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Ma…. 51 references. The full text is freely available (open access, CC BY 4.0). Funded by: Europe Research and Innovation program Cancer Mission, China Scholarship Council, National Key Research & Development Program of China.
Abstract (original language)
Nucleic acid therapeutics offer unique opportunities to develop personalized precision therapies by responding specifically and effectively at the gene level to evolving pathogens. However, many nucleic acid drugs employ a single‐target strategy, which is effective in monogenic disorders, yet can be ineffective in treating diseases characterized by complex and interacting molecular events. Nucleic acid combinations capable of simultaneously modulating multiple pathways and harnessing concerted effects constitute a promising approach to combatting complex, dynamically evolving and heterogeneous diseases. Here, we report a combination strategy utilizing small activating RNA to activate tumor suppressor genes alongside small interfering RNA to silence oncogenes for therapeutic potential and clinical relevance in cancer treatment using patient‐derived tumor models of pancreatic cancer. Transcriptomic and proteomic profiling of individual patient tumors enabled rational design of patient‐specific combinations, which exhibited superior anticancer efficacy through coordinated regulation of multiple genes. Importantly, diverse combinations were tailored to individual patient tumor models to elicit therapeutic responses, while certain specific combinations demonstrated therapeutic efficacy across different tumor models that shared similar genetic features, highlighting the flexibility and pan‐treatment potential. Our findings not only confirm the efficacy of the combination approach for cancer treatment, but also underscore its potential applicability to other complex malignancies.
Subjects
Author keywords
Authors and institutions
- Aix Marseille University, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille (CINaM), UMR 7325, Equipe Labellisée Ligue Contre le Cancer, Marseille, France.
- Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France.
- State Key Laboratory of Natural Medicines, Joint International Research Laboratory of Target Discovery and New Drug Innovation (Ministry of Education), Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Ce…
- Center For Pharmacological and Botanical Studies, Faculty of Medicine, National Scientific and Technical Research Council, University of Buenos Aires, Buenos Aires, Argentina.
- MiNA Therapeutics Ltd, Translation & Innovation Hub, London, UK.
- Department of Surgery and Cancer, Hammersmith Hospital, Imperial College London, London, UK.
Funding
- Europe Research and Innovation program Cancer Mission
- China Scholarship Council
- National Key Research & Development Program of China
- Europe Marie Skłodowska-Curie Innovative Training Network
Cite
APA
Wu, J., Chen, J., Elkihel, A., Lan, W., Fraunhoffer, N., Zhu, D., Lian, B., Galanakou, C., Bian, Z., Liu, X., Gayet, O., Moubri, L., Roques, J. A., Reebye, V., Habib, N., Liu, X., Dusetti, N., Iovanna, J. L., & Peng, L. (2026). Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment. Advanced Science. https://doi.org/10.1002/advs.76840
Vancouver
Wu J, Chen J, Elkihel A, Lan W, Fraunhoffer N, Zhu D, et al. Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment. Advanced Science. 2026. doi:10.1002/advs.76840
BibTeX
@article{Wu2026,
author = {Wu, Jing and Chen, Jiaxuan and Elkihel, Abdechakour and Lan, Wenjun and Fraunhoffer, Nicolas and Zhu, Dandan and Lian, Baoping and Galanakou, Christina and Bian, Zhancun and Liu, Xi and Gayet, Odile and Moubri, Loic and Roques, Julie Aglietti and Reebye, Vikash and Habib, Nagy and Liu, Xiaoxuan and Dusetti, Nelson and Iovanna, Juan Lucio and Peng, Ling},
title = {Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76840}
}
EUVIMED